Tamoxifen is a nonsteroidal anti-estrogenic drug used for adjuvant treatment of breast cancer and recently as a chemopreventative agent for breast cancer and, on an investigational basis, for other cancers. To date there are case reports of hypertriglyceridemia and fatty liver disease in tamoxifen users. Fatty liver is associated with visceral obesity and other components of the metabolic syndrome. Here we evaluated steatosis and adipose tissue distribution by CT scan in a crosssectional study of 32 women on tamoxifen and 39 control women. Tamoxifen users had more visceral adipose tissue (VAT) and more liver fat than controls. This is the ®rst study to demonstrate that fatty liver and intra-abdominal fat accumulation are common in breast cancer patients receiving tamoxifen. Prospective studies of tamoxifen should monitor metabolic changes in obese women with or without breast cancer.
Introduction
Tamoxifen is a nonsteroidal anti-estrogenic drug that is metabolized in the liver. It has been used for decades as adjuvant treatment of breast cancer in menopausal women and more recently as a chemopreventive agent. 1 Among the rare side-effects of tamoxifen are listed increased risks of endometrial cancer and thrombotic disorders and case reports of severe hypertriglyceridemia 2, 3 and liver disease. 4, 5 Previously we have demonstrated an increase in fatty liver in a series of patients taking tamoxifen for breast cancer. 6 Ogawa et al subsequently demonstrated development of fatty liver in a prospective study of women given tamoxifen for this disease. 7 Because of the relationships between fatty liver and fat distribution 8 and other components of the metabolic syndrome X of obesity, 9 we investigated whether tamoxifen use was associated with any metabolic abnormalities related to fatty liver disease.
Methods
Patients Thirty-two post-menopausal women (age: 59 AE 2.0 y; mean AE s.e.m.) taking tamoxifen for estrogen receptor positive breast cancer for a mean 30 months (range: 4 ± 84 months) who had had computed tomography (CT), and a convenience sample of 39 women (age 57 AE 2.2 y; NS) having CT scans for similar indications were entered into the study. Patients and controls were excluded if they had any evidence of liver disease on physical examination, were taking steroids, or had a history of signi®cant ethanol consumption or other hepatotoxic exposure. We recorded any history of diabetes, hypertension or dyslipidemia in patients and controls.
Computed tomography CT scans were performed on a General Electric 9800 quick Hi-Lyte scanner 1 or a PACE 1 scanner. The mean of six regions of interest (ROI) in the liver, de®ned as homogeneous, representative areas avoiding blood vessels, was calculated. Absolute liver density is expressed in Houns®eld units (HU), and is inversely related to the degree of fatty in®ltration. Visceral (VAT) fat area was calculated using a single slice at lumbar spinal levels L1 ± L2, assigning HU values of À90 to À190 to fat and manually tracing these regions separately.
Statistics
Multiple regression analysis was performed to evaluate correlations between liver density, VAT and body mass index (BMI). Means were compared by t-tests, while chi-square analysis was used to evaluate differences between frequency of diabetes and hypertension in the two groups. Analyses were performed with SPSS version 8.0. Means and standard errors are given.
Results
The women taking tamoxifen were heavier, had larger areas of visceral adipose tissue and signi®cantly less dense livers than the control women (Table 1) . Diabetes was approximately three times as prevalent in the tamoxifen users while there was no difference in hypertension or dyslipidemia.
Because of the signi®cant difference in BMI between the groups, we studied a subgroup of 14 tamoxifen users and 10 controls matched for BMI (27.5 AE 0.6 vs 26.7 AE 08; NS) and age (61.8 AE 2.9 vs 62.1 AE 2.0; NS). We found similar statistically signi®cant differences in VAT (126 AE 14.7 vs 79 AE 9.1; P 0.01) and liver density (34.6 AE 5 vs 51.1 AE 1.6; P 0.01) to those in the whole population. However, diabetes was present in 20% of subjects in both groups.
Liver density was inversely correlated with BMI (r À0.58; P 0.000) and VAT (r À0.52; P 0.000; Figure 1 ).
There were no relationships between duration of tamoxifen use and liver density or VAT.
Discussion
This is the ®rst study to demonstrate that fatty liver and intra-abdominal fat accumulation are common in breast cancer patients receiving tamoxifen. Two possible explanations come to mind. Tamoxifen, through its anti-estrogenic effects, may cause male-pattern, visceral obesity, accompanied by fatty liver and hypertriglyceridemia. Indeed, hypertriglyceridemia of varying magnitude has been described in population studies 10, 11 and in case reports, 2,3 although we were unable to demonstrate any difference in dyslipidemia between our groups. An alternative explanation is that women with central fat distribution, hypertriglyceridemia and increased levels of sex hormones are at risk for breast Figure 1 Relationship between liver density and visceral fat in tamoxifen users and controls (y 1.43x 60.74; r À0.52, P`0.000). Tamoxifen and body fat MC Nguyen et al cancer 12 and thus are likely to receive tamoxifen. Such women may also be more susceptible to the various known side-effects of tamoxifen, including fatty liver, thrombotic disorders and endometrial cancer 1 Ð all associated with the metabolic Syndrome X. Our relatively small study, however, did not demonstrate any difference in diabetes when adjusting for BMI and age.
A prospective longitudinal study is needed to determine whether tamoxifen induces metabolic abnormalities over the long term in obese patients or whether patients with the metabolic syndrome are at increased risk for complications of tamoxifen. Studies investigating chemopreventive tamoxifen should stratify patients according to BMI and fat distribution and monitor metabolic parameters.
